摘要
Abstract
Objective To investigate the efficacy and safety of NVB and cisplatin in the treatment of patients with TNBC resistant to anthracyclines. Methods Sixty patients with histoimmunochemical proved triple-negative breast cancer were enrolled, and they all failed to response to anthracyclines. All the patients received 21 days treatment per cycle of navelbine 25 mg/m2, dl and d8, and cisplatin 80 mg/m2 ,d3 -5. SPSS 16. 0 was applied to analyze the data gained in the research. Results A total of 325 cycles were given to 60 patients (median 5 months, ranged 4-6 cycles). The treatment response was evaluable in all patients. Of all the patients, 2 received complete remission (CR), 25 received partial remission (PR), 21 had stable disease (SD), 12 had progressive disease (PD). Response rate (CR + PR) accounted for 45.4% of the whole group. The median time to progress (TTP) was 9 months, while 95% CI ranged from 8. 0 to 10.0 months. The major adverse events were grade I -II bone marrow suppression, peripheral neurotoxicity, nausea and vomiting. Conclusion The combination of NVB and cisplatin is an effective and tolerable regimen for the patients with TNBC resistant to anatracyclines.关键词
乳腺肿瘤/药物疗法/诺维本/治疗应用/顺铂/抗药性/生活质量Key words
breast neoplasms/drug therapy/ navelbine/therapeutic use/ cisplatin/ drug resistance/ quality of life分类
医药卫生
